Whole Tumor Antigen Vaccines: Where Are We?
With its vast amount of uncharacterized and characterized T cell epitopes available for activating CD4+ T helper and CD8+ cytotoxic lymphocytes simultaneously, whole tumor antigen represents an attractive alternative source of antigens as compared to tumor-derived peptides and full-length recombinan...
Main Authors: | Cheryl Lai-Lai Chiang, George Coukos, Lana E. Kandalaft |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2015-04-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | http://www.mdpi.com/2076-393X/3/2/344 |
Similar Items
-
Vaccines as Priming Tools for T Cell Therapy for Epithelial Cancers
by: Lana E. Kandalaft, et al.
Published: (2021-11-01) -
Rethinking Antigen Source: Cancer Vaccines Based on Whole Tumor Cell/tissue Lysate or Whole Tumor Cell
by: Lu Diao, et al.
Published: (2023-08-01) -
COVID-19 Vaccines: Where Did We Stand at the End of 2023?
by: Kenneth Lundstrom
Published: (2024-01-01) -
Vaccination Therapy for Acute Myeloid Leukemia: Where Do We Stand?
by: Kordelia Barbullushi, et al.
Published: (2022-06-01) -
Integrating Cancer Vaccines in the Standard-of-Care of Ovarian Cancer: Translating Preclinical Models to Human
by: Cheryl Lai-Lai Chiang, et al.
Published: (2021-09-01)